Two common empiric intraperitoneal antibiotic regimens for suspected PD peritonitis?

Two common empiric intraperitoneal antibiotic regimens for suspected PD peritonitis?

• A. Oral amoxicillin alone.
• B. Intraperitoneal vancomycin plus a third-generation cephalosporin (e.g., ceftazidime) or vancomycin plus an aminoglycoside.
• C. Intraperitoneal cephalexin alone.
• D. Intravenous vancomycin monotherapy.

Answer: (B)

When suspected PD peritonitis, the aim is immediate broad coverage of both Gram-positive cocci and Gram-negative rods, delivered directly into the peritoneal cavity for high local concentrations. Using intraperitoneal vancomycin provides strong coverage of Gram-positive organisms, including MRSA, while adding a second agent that targets Gram-negative bacteria—such as a third-generation cephalosporin like ceftazidime or an aminoglycoside—ensures the common Gram-negative pathogens are covered. Delivering these drugs intraperitoneally is preferred because it achieves the necessary peritoneal concentrations to treat the infection effectively. Options that rely on only oral antibiotics, or on a single agent that doesn’t cover both groups, are insufficient for empiric therapy. Intravenous vancomycin alone won’t reliably address peritoneal Gram-negative organisms, and an intraperitoneal agent that targets only Gram-positives wouldn’t cover the typical Gram-negative pathogens as well. Thus, two common empiric regimens are intraperitoneal vancomycin plus a cephalosporin (e.g., ceftazidime) or intraperitoneal vancomycin plus an aminoglycoside.

When suspected PD peritonitis, the aim is immediate broad coverage of both Gram-positive cocci and Gram-negative rods, delivered directly into the peritoneal cavity for high local concentrations. Using intraperitoneal vancomycin provides strong coverage of Gram-positive organisms, including MRSA, while adding a second agent that targets Gram-negative bacteria—such as a third-generation cephalosporin like ceftazidime or an aminoglycoside—ensures the common Gram-negative pathogens are covered. Delivering these drugs intraperitoneally is preferred because it achieves the necessary peritoneal concentrations to treat the infection effectively.

Options that rely on only oral antibiotics, or on a single agent that doesn’t cover both groups, are insufficient for empiric therapy. Intravenous vancomycin alone won’t reliably address peritoneal Gram-negative organisms, and an intraperitoneal agent that targets only Gram-positives wouldn’t cover the typical Gram-negative pathogens as well. Thus, two common empiric regimens are intraperitoneal vancomycin plus a cephalosporin (e.g., ceftazidime) or intraperitoneal vancomycin plus an aminoglycoside.